Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy.

被引：0
|
作者：
Kaufman, Howard L.
Russell, Jeffrey
Hamid, Omid
Bhatia, Shailender
Terheyden, Patrick
D'Angelo, Sandra P.
Shih, Kent C.
Lebbe, Celeste
Linette, Gerald P.
Milella, Michele
Brownell, Isaac
Lewis, Karl D.
Lorch, Jochen H.
von Heydebreck, Anja
Mahnke, Lisa
Nghiem, Paul
机构：
[1] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] Angeles Clin & Res Inst, Los Angeles, CA USA
[4] Univ Washington, Med Ctr, South Lake Union, Seattle, WA 98195 USA
[5] Univ Lubeck, Lubeck, Germany
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[8] CHU Paris, GH St Louis Lariboisiere F Widal, Hosp St Louis, Paris, France
[9] Univ Washington, Sch Med, Seattle, WA 98195 USA
[10] Ist Nazl Tumori Regina Elena IRCCS, Rome, Italy
[11] Natl Canc Inst, Bethesda, MD USA
[12] Univ Colorado Denver, Sch Med, Aurora, CO USA
[13] Dana Farber Canc Inst, Boston, MA 02115 USA
[14] Merck KGaA, Darmstadt, Germany
[15] EMD Serono, Billerica, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 07期
关键词：
D O I：
10.1200/JCO.2017.35.7_suppl.80
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
80
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
    Kaufman, Howard L.
    Russell, Jeffery
    Hamid, Omid
    Bhatia, Shailender
    Terheyden, Patrick
    D'Angelo, Sandra P.
    Shih, Kent C.
    Lebbe, Celeste
    Linette, Gerald P.
    Milella, Michele
    Brownell, Isaac
    Lewis, Karl D.
    Lorch, Jochen H.
    Chin, Kevin
    Mahnke, Lisa
    von Heydebreck, Anja
    Cuillerot, Jean-Marie
    Nghiem, Paul
    LANCET ONCOLOGY, 2016, 17 (10): : 1374 - 1385
  • [2] Avelumab for the treatment of metastatic Merkel cell carcinoma
    Cordes, L. M.
    Gulley, J. L.
    DRUGS OF TODAY, 2017, 53 (07) : 377 - 383
  • [3] Avelumab: A Review in Metastatic Merkel Cell Carcinoma
    Shirley, Matt
    TARGETED ONCOLOGY, 2018, 13 (03) : 409 - 416
  • [4] Avelumab: A Review in Metastatic Merkel Cell Carcinoma
    Matt Shirley
    Targeted Oncology, 2018, 13 : 409 - 416
  • [5] Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
    Tereza Lanitis
    Irina Proskorovsky
    Apoorva Ambavane
    Matthias Hunger
    Ying Zheng
    Murtuza Bharmal
    Hemant Phatak
    Advances in Therapy, 2019, 36 : 2327 - 2341
  • [6] Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
    Lanitis, Tereza
    Proskorovsky, Irina
    Ambavane, Apoorva
    Hunger, Matthias
    Zheng, Ying
    Bharmal, Murtuza
    Phatak, Hemant
    ADVANCES IN THERAPY, 2019, 36 (09) : 2327 - 2341
  • [7] Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
    Bullement, Ash
    Nathan, Paul
    Willis, Anna
    Amin, Amerah
    Lilley, Cameron
    Stapelkamp, Ceilidh
    Hatswell, Anthony
    Pescott, Chris
    Bharmal, Murtuza
    PHARMACOECONOMICS-OPEN, 2019, 3 (03) : 377 - 390
  • [8] Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
    Ash Bullement
    Paul Nathan
    Anna Willis
    Amerah Amin
    Cameron Lilley
    Ceilidh Stapelkamp
    Anthony Hatswell
    Chris Pescott
    Murtuza Bharmal
    PharmacoEconomics - Open, 2019, 3 : 377 - 390
  • [9] A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan
    Chang, Wen-Cheng
    Lin, Amy Y.
    Hsu, Jason C.
    Wu, Chiao-En
    Goh, Connie
    Chou, Patrick
    Kuo, Kaitlin
    Chang, Anne
    Palencia, Roberto
    CANCER REPORTS, 2021, 4 (06)
  • [10] BUDGET IMPACT ANALYSIS OF AVELUMAB IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN THE US
    Bharmal, M.
    D'Angelo, S. P.
    Phatak, H.
    VALUE IN HEALTH, 2017, 20 (09) : A424 - A424
12345